Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction (2019)
- Authors:
- Autor USP: NICOLAU, JOSÉ CARLOS - FM
- Unidade: FM
- DOI: 10.1056/NEJMoa1911303
- Subjects: INSUFICIÊNCIA CARDÍACA; DIABETES MELLITUS NÃO INSULINO-DEPENDENTE; PROTEÍNAS DE TRANSPORTE; RESULTADO DE TRATAMENTO; ESTUDOS PROSPECTIVOS
- Agências de fomento:
- Vifor Pharma
- Boehringer IngelheimBoehringer Ingelheim
- Eidos Therapeutics
- Sanofi Pasteur
- Mesoblast
- Lonestar Heart
- Ionis Pharmaceuticals
- Celladon
- Bellerophon Therapeutics
- Cytokinetics
- BayerBayer AG
- Theracos
- NovartisNovartis
- MyoKardia
- GlaxoSmithKlineGlaxoSmithKline
- Gilead SciencesGilead Sciences
- Bristol-Myers SquibbBristol-Myers Squibb
- AmgenAmgen
- Alnylam Pharmaceuticals
- AstraZenecaAstraZeneca
- Language: Inglês
- Imprenta:
- Source:
- Título: New england journal of medicine
- ISSN: 0028-4793
- Volume/Número/Paginação/Ano: v. 381, n. 21, p. 1995-2008, 2019
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
MCMURRAY, J. J. V et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New england journal of medicine, v. 381, n. 21, p. 1995-2008, 2019Tradução . . Disponível em: https://doi.org/10.1056/NEJMoa1911303. Acesso em: 22 jan. 2026. -
APA
Mcmurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Kober, L., Kosiborod, M. N., Martinez, F. A., et al. (2019). Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New england journal of medicine, 381( 21), 1995-2008. doi:10.1056/NEJMoa1911303 -
NLM
Mcmurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Nicolau JC. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction [Internet]. New england journal of medicine. 2019 ; 381( 21): 1995-2008.[citado 2026 jan. 22 ] Available from: https://doi.org/10.1056/NEJMoa1911303 -
Vancouver
Mcmurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Nicolau JC. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction [Internet]. New england journal of medicine. 2019 ; 381( 21): 1995-2008.[citado 2026 jan. 22 ] Available from: https://doi.org/10.1056/NEJMoa1911303 - Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
- Dabigatran dual therapy vs warfarin triple therapy post-percutaneous coronary intervention in patients with atrial fibrillation with/without a proton pump inhibitor: a pre-specified analysis of the RE-DUAL PCI trial
- Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial
- Oclusão de comunicação interventricular pós-infarto com prótese percutânea CERA
- Myocardial Viability and Survival in Ischemic Left Ventricular Dysfunction
- Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial
- Reduction in aubtypes and sizes of myocardial infarction with ticagrelor in PEGASUS-TIMI 54
- I Diretriz da Sociedade Brasileira de Cardiologia sobre processos e competências para a formação em cardiologia no Brasil: resumo executivo
- Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery: Results From the PLATO (Platelet Inhibition and Patient Outcomes) Trial
- Spontaneous MI After Non–ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial
Informações sobre o DOI: 10.1056/NEJMoa1911303 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
